Gastric cancer or adenocarcinoma of the gastroesophageal junction
Conditions
Interventions
ctDNA-MRD negative cohort:SOX regimen chemotherapy for 8 cycles.
ctDNA-MRD positive cohort ( randomized cohort ) Group A:SOX regimen chemotherapy for 8 cycles.
ctDNA-MRD positive cohort (randomized cohort) Group B:SOX regimen chemotherapy for 8 cycles,followed by S-1 oral treatment for 8 cycles.
Sponsors
Beijing Friendship Hospital ,Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age greater than 18 years old, men and women are not limited. 2.Pathological diagnosis of gastric or gastroesophageal junction adenocarcinoma . 3.Radical R0 resection, pathological stage II or III ( according to AJCC 8th version ) . 4.physical condition score ( ECOG ) <=1. 5.Samples with complete follow-up data. 6.Patients or family members, who can understand the research program and are willing to participate in this study, provide written informed consent.
Exclusion criteria
Exclusion criteria: 1.Patients received systemic neoadjuvant chemotherapy or chemoradiotherapy before operation. 2.Pregnant or lactating female patients. 3.History of other malignant tumors in the past 5 years. 4.Any severe or uncontrolled systemic disease that the researchers believe may significantly affect the risk / benefit balance of patients, such as severe heart disease ( NYHA class III-IV ), active severe infection, decompensated liver disease / renal failure, etc. 5.Patients or family members can not understand the conditions and objectives of this study. 6.The researchers believe that is not suitable for the group.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease-Free Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival;Adverse events related to chemotherapy; | — |
Countries
China
Contacts
Public ContactWeiDeng
Beijing Friendship Hospital ,Capital Medical University
Outcome results
None listed